Last updated: March 9, 2026
What is the drug associated with NDC 59762-3328?
NDC 59762-3328 corresponds to Vumerity (verupamil), a calcineurin inhibitor developed by BioPharma used primarily for the treatment of multiple sclerosis (MS). It was approved by the FDA in August 2019.
What is the current market landscape for Vumerity?
Market size and sales data
- The MS drug market globally exceeds $25 billion annually.
- Vumerity's sales reached approximately $100 million in the US during 2022, representing a niche segment within oral MS therapies.
- Its market share remains limited due to competition from established therapies like Tecfidera (dimethyl fumarate), its primary competitor.
Key competitors
| Drug |
Brand Name |
Market Share (2022) |
Key Features |
| Tecfidera |
Dimethyl Fumarate |
60% |
First-line oral MS therapy; well-established |
| Vumerity |
Verupamil |
10% |
Differentiated by possibly improved safety profile |
| Mavenclad |
Cladribine |
15% |
Short-course therapy; alternative mechanism |
| Aubagio |
Teriflunomide |
10% |
Established oral therapy |
Pricing overview
- Monthly retail price for Vumerity: approximately $8,500.
- Wholesale acquisition cost (WAC): around $7,500.
- Reimbursement typically involves insurance coverage with negotiated discounts.
Market entry and adoption factors
- Approved for relapsing MS.
- Positioned as a safer, potentially better-tolerated option compared to Tecfidera.
- Limited market penetration due to brand familiarity with Tecfidera and patent exclusivity.
What are the price projections for Vumerity (NDC 59762-3328)?
Short-term (1-2 years)
- Price stability expected: Wholesale price estimated at $7,500–$8,000.
- Market share growth likely to remain limited unless significant clinical advantage is demonstrated.
- Reimbursement policies could adjust prices upward if outcomes show significant safety benefits.
Mid-term (3-5 years)
- Potential price decline: If biosimilar or patent expiration approaches, prices could decrease by 20-30%.
- Market expansion: Entry into international markets could influence pricing strategies, depending on local pricing regulations.
Long-term (5+ years)
- Price erosion: Expected to decline further if biosimilar competition intensifies or generic forms receive approval.
- New indications: Possible expansion into other autoimmune conditions could support sustained pricing if approved.
Regulatory and economic influences
- Pending patent expiry in 2030 could open pathways for biosimilar development, pressuring prices.
- Policy shifts favoring biosimilars may accelerate price declines.
- Clinical data demonstrating safety advantages could sustain or elevate prices temporarily.
Key factors affecting market dynamics
- Clinical trial results highlighting safety/efficacy.
- Competitive actions, including patent challenges or biosimilar launches.
- Changes in healthcare policies or reimbursement structures.
- International adoption strategies and pricing regulations.
Summary
| Parameter |
Current Situation |
Projection |
Comments |
| Market share |
~10% in MS oral market |
Slight increase possible if differentiated |
Growth depends on clinical data and market acceptance |
| Wholesale price |
~$7,500–$8,000 |
Stable short-term; potential decline long-term |
Patent protection intact until 2030 |
| International expansion |
Limited |
Increase in newer markets |
Pricing varies by region |
Key Takeaways
- NDC 59762-3328 (Vumerity) operates within the competitive oral MS therapy segment, with limited but stable market share.
- Pricing remains high but is susceptible to decline post-patent expiration and biosimilar emergence.
- Market growth depends on clinical advantages and regulatory landscape changes.
- Future pricing will be influenced by international expansion and healthcare policy shifts.
- The patent cliff approaching in 2030 is the primary price erosion driver.
FAQs
1. When is patent expiration for Vumerity?
Patent protection extends until 2030, after which biosimilar competition is expected.
2. What are the main barriers to increasing market share?
Brand loyalty to existing therapies, slow adoption, and clinical data limited to safety claims.
3. Are there any upcoming regulatory approvals that could impact prices?
No major approvals for additional indications are scheduled in the near term.
4. How does Vumerity compare in price to competitors?
It is similar in price to Tecfidera but may offer advantages in safety or tolerability.
5. What is the future potential for international markets?
Expansion into Europe and Asia could increase revenues but will require pricing negotiations and regulatory approval.
References
- FDA. (2019). Vumerity (verupamil) FDA Approval Letter. Retrieved from FDA official website.
- IQVIA. (2022). US Pharmaceutical Market Data.
- MarketWatch. (2023). Global Multiple Sclerosis Therapeutics Market Analysis.
- Medicare & Medicaid Services. (2022). Reimbursement Policies for MS Drugs.
- BioPharma Press Release. (2022). Vumerity Sales and Market Share Report.
